BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Bay Area Biotech Forges Multi-Year Research Deal with Genentech

  A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal.

  December 19, 2017

   · 

  2 min read

   · 

  Alex Keown
• Pharm Country

  Pfizer Announces New $10B Share Buyback, Hikes Dividend

  Pfizer’s announcement comes ahead of the Trump administration’s long-awaited bill to lower taxes.

  December 19, 2017

   · 

  1 min read
• 

  Drug Development

  Shire’s Hunter Syndrome Treatment Failed Phase II/III Goals

  An experimental treatment to address cognitive impairment in pediatric patients diagnosed with the rare disease known as Hunter syndrome failed a key trial, Shire PLC announced this morning.

  December 19, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Genetown

  With a Collaboration Deal in Place with Merck, Cue Biopharma Plans $60 Million IPO

  Cue BioPharma is on a roll, having recently signed a deal with Merck and is planning an IPO to raise up to $60M.

  December 19, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Roche Boss Claims pRED Division Soon to Emerge from Genentech’s Shadow

  The fact that Roche has separate R&D units has been the topic of second-guessing on the part of observers and analysts.

  December 19, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  McKesson Wins $400M Maximum Digital Imaging, Archiving DoD Contract

  The award comes in the form of a five-year base fixed-price with economic-price-adjustment, indefinite-delivery and indefinite-quantity contract, with a single five-year option period, according to a DoD release.

  December 19, 2017

   · 

  1 min read
• 

  FDA

  Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S.

  The FDA broke new ground today with a first-of-its-kind therapy for eye disease.

  December 19, 2017

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  Surprise! FDA Clears Launch For Portola’s Potential Multibillion-Dollar Drug Next Month

  The FDA continues to hand out some early Christmas presents to pharma companies.

  December 19, 2017

   · 

  3 min read

   · 

  Alex Keown
• 

  BioCapital

  Maryland’s Precision Medicine Group Lands $275M

  The round was led by Berkshire Partners and TPG Growth, with participation from its co-founders and management team, as well as original investors Oak Investment Partners and J.H. Whitney.

  December 19, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Policy

  Roche, Shire Patent Fight Escalates Over Haemophilia Drug

  Roche’s patent dispute with Shire over the new haemophilia drug Hemlibra has escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some patients from getting its medicine.

  December 19, 2017

   · 

  1 min read